PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- PeptiDream, PDRadiopharma and Curium Group have enrolled the first patient in a registrational Phase 2 clinical trial of 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA-expressing prostate cancer cells in Japan. - The open-label, single-arm study will evaluate sensitivity, specificity, and safety in approximately 70 patients with newly diagnosed unfavorable intermediate to very high-risk prostate cancer scheduled for prostatectomy. - The diagnostic agent is being developed alongside its therapeutic counterpart 177Lu-PSMA-I&T, which recently met its primary endpoint in a global Phase 3 ECLIPSE trial for metastatic castration-resistant prostate cancer. - Japan sees approximately 90,000-100,000 new prostate cancer cases annually, with significant unmet medical need for improved diagnostic and therapeutic options in this patient population.
- Peptide drug conjugates represent a novel targeted therapy approach that combines disease-targeting peptides with small molecule drugs to deliver treatments directly to diseased tissues while minimizing systemic toxicity. - The global peptide drug conjugate market has experienced remarkable growth of over 300% absolute growth and 27% CAGR from 2018-2024, with market opportunities exceeding $1.4 billion. - Two peptide drug conjugates have received regulatory approval as of May 2025: Novartis's Lutathera for gastroenteropancreatic neuroendocrine tumors and Oncopeptides' Pepaxti for multiple myeloma. - More than 30 peptide drug conjugate candidates are currently advancing through various stages of clinical trials, primarily focused on oncology applications but expanding into neurodegenerative and inflammatory disorders.
- Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases. - This marks Roche's second major molecular glue deal in a month, following a similar $2 billion alliance with Orionis Biosciences, demonstrating the company's strategic push to establish leadership in this emerging therapeutic category. - Monte Rosa will lead discovery and preclinical activities using its QuEEN platform, with Roche taking over late-stage development of candidates that can potentially address the 80% of human proteins currently inaccessible to traditional drug development approaches.
- Curium and PDRadiopharma are partnering to advance clinical development and commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T theranostics in Japan. - 177Lu-PSMA-I&T is currently in Phase 3 ECLIPSE trial for metastatic castration-resistant prostate cancer (mCRPC), comparing it to standard hormone therapy. - 64Cu-PSMA-I&T is being evaluated in Phase 3 SOLAR RECUR and SOLAR STAGE trials for recurrent and newly diagnosed prostate cancer, respectively. - The collaboration aims to accelerate the availability of these targeted radiopharmaceuticals for prostate cancer diagnosis and treatment in Japan.
